Search results for "Tatin"

showing 10 items of 700 documents

Influences of histone deacetylase inhibitors and resveratrol on DNA repair and chromatin compaction

2013

Accessibility of DNA is a prerequisite for both DNA damage and repair. Therefore, the chromatin structure is expected to have major impact on both processes, with opposite consequences for the stability of the genome. To analyse the influence of chromatin compaction on the generation and repair of various types of DNA modifications, we modulated the global chromatin structure of AS52 Chinese hamster ovary cells and HeLa cells by treatment with either histone deacetylase inhibitors or resveratrol and measured the repair kinetics of (i) pyrimidine dimers induced by ultraviolet B, (ii) oxidised purines generated by photosensitisation and (iii) single-strand breaks induced by H2O2, using an alk…

DNA RepairUltraviolet RaysDNA damageDNA repairHealth Toxicology and MutagenesisCarbazolesCHO CellsHydroxamic AcidsToxicologyChromatin remodelingCricetulusStilbenesHistone H2AGeneticsmedicineAnimalsDeoxyribonuclease IHumansDNA Breaks Single-StrandedGenetics (clinical)EpigenomicsbiologyChemistryMolecular biologyChromatinCell biologyProliferating cell nuclear antigenChromatinHistone Deacetylase InhibitorsButyratesTrichostatin APyrimidine DimersResveratrolbiology.proteinHeLa Cellsmedicine.drugMutagenesis
researchProduct

Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide

2006

Background and purpose: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are frequently used lipid-lowering drugs. Moreover, they exert pleiotropic effects on cellular stress responses and death. Here, we analysed whether lovastatin affects the sensitivity of primary human endothelial cells (HUVEC) to the anticancer drug doxorubicin. Experimental approach: We investigated whether pretreatment of HUVEC with low dose of lovastatin influences the cellular sensitivity to doxorubicin. To this end, cell viability, proliferation and apoptosis as well as DNA damage-triggered stress response were analysed. Key results: Lovastatin reduced the cytotoxic potency of doxorub…

DNA ReplicationCell SurvivalDNA damageApoptosisBiologyPharmacologypolycyclic compoundsmedicineHumansTopoisomerase II InhibitorsDoxorubicinLovastatinEtoposideEtoposideFluorescent DyesPharmacologyAntibiotics AntineoplasticReverse Transcriptase Polymerase Chain ReactionTopoisomeraseCell CycleEndothelial Cellsnutritional and metabolic diseasesAntimutagenic AgentsFibroblastsCell cycleResearch PapersAntineoplastic Agents PhytogenicDoxorubicinDrug Resistance NeoplasmHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)LovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsTopoisomerase-II InhibitorReactive Oxygen SpeciesFluorescein-5-isothiocyanateDNA Damagemedicine.drugBritish Journal of Pharmacology
researchProduct

Ultraviolet light-induced apoptotic death is impaired by the HMG-CoA reductase inhibitor lovastatin.

2003

HMG-CoA reductase inhibitors (i.e., statins) attenuate C-terminal isoprenylation of Rho GTPases, thereby inhibiting UV-C-induced activation of c-Jun-N-terminal kinases/stress-activated protein kinases (JNKs/SAPKs). Inhibition of UV-C-triggered JNK/SAPK activation by lovastatin is due to inhibition of Rac-SEK1/MKK4-mediated phosphorylation of JNKs/SAPKs at Thr183/Tyr185. UV-C-stimulated phosphorylation of p38 kinase (Thr180/Tyr182) is also impaired by lovastatin. Cell killing provoked by UV-C irradiation was significantly inhibited by lovastatin. This was paralleled by a reduced frequency of chromosomal aberrations, accelerated recovery from UV-C-induced transient replication blockage, inhib…

DNA ReplicationUltraviolet Raysp38 mitogen-activated protein kinasesBiophysicsApoptosisCHO CellsBiochemistryp38 Mitogen-Activated Protein KinasesCricetinaemedicineUltraviolet lightAnimalsMitogen-Activated Protein Kinase 8LovastatinMolecular BiologyCaspasebiologyKinaseCell BiologyCell biologyrac GTP-Binding ProteinsEnzyme ActivationCell killingApoptosisCaspasesHMG-CoA reductasebiology.proteinLovastatinHydroxymethylglutaryl-CoA Reductase InhibitorsMitogen-Activated Protein Kinasesmedicine.drugBiochemical and biophysical research communications
researchProduct

Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)

2022

AbstractDyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowe…

Diabetes Mellitus Type 2 / diagnosisDyslipidemias / drug therapyEndocrinology Diabetes and Metabolism610 Medicine & health2705 Cardiology and Cardiovascular MedicineCardiovascular risk Diabetes Individual therapy approach Lipid lowering therapy StatinsHumansIndividual therapy approachDyslipidemiasHypolipidemic AgentsDiabetes Mellitus Type 2 / epidemiologyDiabetesStatinsCholesterol LDLCardiovascular riskAtherosclerosisDyslipidemias / diagnosis2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 22724 Internal MedicineDyslipidemias / epidemiology10209 Clinic for CardiologyProprotein Convertase 9Diabetes Mellitus Type 2 / drug therapyCardiology and Cardiovascular MedicineLipid lowering therapy
researchProduct

Synthesis of N-acyl Derivatives of Aminocombretastatin A-4 and Study of their Interaction with Tubulin and Downregulation of c-Myc.

2021

11 p.-9 fig.-4 tab.

Down-RegulationAntineoplastic AgentsMicrotubule dynamicsStructure-Activity RelationshipDownregulation and upregulationMicrotubuleTubulinCell Line TumorDrug DiscoveryHumansMTT assayAminocombretastatin A-4Cell ProliferationbiologyChemistryCell growthIn vitroTubulin ModulatorsMolecular Docking SimulationTubulinc-MycBiochemistryCell cultureDocking (molecular)biology.proteinDrug Screening Assays AntitumorAnti-proliferative activityAnti-mitoticMedicinal chemistry (Shariqah (United Arab Emirates))
researchProduct

Magnētiskā šķidruma pilieni rotējošā laukā: teorija, eksperimenti un simulācijas

2022

Magnētiskā šķidruma pilieni ir reizē deformējami un ietekmējami ar ārējo magnētisko lauku, kas tos padara par interesantu materiālu, kas is atradis daudzus pielietojumus mikrofluīdikā. Šajā darbā tiek aplūkota šādu pilienu dinamika rotējošā magnētiskajā laukā. Pilieni tiek pētīti, izmantojot vairākas pieejas - teorētiski, eksperimentāli un izmantojot simulācijas. Kad rotējošais magnētiskais lauks lauks ir vājš un piliena deformācija ir maza, piliena kustība tiek aprēķināta analītiski. Konstatēts, ka piliena formas attīstību laikā regulē trīs nelineāru diferenciālvienādojumu sistēma. Mazo deformāciju tuvinājumā piliena uzvedību kvalitatīvi raksturo viens parametrs, kas ir proporcionāls kapil…

DropletBoundary element methodsRotating fieldFluid and gas mechanicsFerrofluid:NATURAL SCIENCES::Physics [Research Subject Categories]
researchProduct

Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision

2008

OBJECTIVE: To assess whether the prescribing pattern of lipid-lowering drugs (LLD) changed after reimbursement criteria revision in a general practice in southern Italy. METHODS: From the Caserta-1 Local Health Service database, 93 general practitioners (GPs) who had consistently sent data about their patients during the years 2003-2005 were recruited. Prevalence of use and incidence of new treatments were calculated for each year, stratified by three drug cohorts: statins, omega-3 fatty acids, and fibrates. Subanalyses by gender, age, and indication of use were performed. RESULTS: Overall, 1-year prevalence of LLD use increased from 2003 to 2004. After reimbursement criteria revision (Nove…

Drug Utilizationmedicine.medical_specialtyPediatricsStatinSettore MED/09 - Medicina Internamedicine.drug_classMEDLINEstatinsInternal medicineFatty Acids Omega-3EpidemiologyHumansMedicinePharmacology (medical)RosuvastatinLipid-lowering drug Statins Omega-3 fatty acids Prevalence of use General practiceClofibrateReimbursementUnsaturated fatty acidHypolipidemic AgentsPharmacologygeneral practiceprevalence of usePrimary Health Careomega-3 fatty acidsbusiness.industryIncidence (epidemiology)General Medicinelipid-lowering drugSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheDrug UtilizationItalyInsurance Health ReimbursementSettore BIO/14 - FarmacologiaHydroxymethylglutaryl-CoA Reductase Inhibitorslipid-lowering drug; statins; omega-3 fatty acids; prevalence of use; general practicebusinessmedicine.drug
researchProduct

Combined pharmacological treatment of heterozygous familial hypercholesterolemia

1990

Combined therapy of heterozygous familial hypercholesterolemia using a non-systemically acting drug (bile acid sequestrants) and a systemically acting one is frequently employed in clinical practice. A brief review of this topic is presented, with particular emphasis on the use of cholestyramine combined with pravastatin, a new HMG CoA reductase inhibitor.

DrugCholestyramineBile acidbiologymedicine.drug_classbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesFamilial hypercholesterolemiaMevalonic acidPharmacologymedicine.diseasePharmacological treatmentchemistry.chemical_compoundchemistryHMG-CoA reductasemedicinebiology.proteinbusinessPravastatinmedicine.drugmedia_common
researchProduct

An overview of statin-induced myopathy and perspectives for the future

2020

Introduction: Statins remain the most commonly prescribed lipid-lowering drug class for the treatment of atherosclerotic cardiovascular disease. Their well-recognized side effects are known as statin-associated muscle symptom (SAMS). Some advances in this field have been made in recent years, but the understanding of the mechanisms has lagged. Investigating the specific role of the anti-HMGCR autoantibody, pharmacokinetic genetic variants, characterization of the known phenotypes of statin toxicity, in relation to clinical markers of disease, is of high importance. Areas covered: We summarized currently available findings (on PubMed) related to SAMS and discussed the therapeutic approaches,…

DrugStatinUbiquinonemedicine.drug_classmedia_common.quotation_subjectHyperlipidemiasDiseasetherapeutic approaches030204 cardiovascular system & hematologyBioinformaticsPharmacogenomic Variants03 medical and health sciences0302 clinical medicineMuscular DiseasesRisk FactorsmedicineAnimalsHumansDrug InteractionsPharmacology (medical)Adverse effectHypolipidemic Agentsmedia_commondrug interactionbusiness.industryGeneral MedicineAtherosclerosisStatin induced myopathystatin-induced myopathyunderlying mechanismDrug classrisk factor030220 oncology & carcinogenesisCoenzyme Q10Hydroxymethylglutaryl-CoA Reductase Inhibitorsmyositis autoantibodieRisk assessmentbusinessstatin-associated muscle symptom
researchProduct

Current treatment of oral candidiasis: a literature review

2014

Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. This pathology has a wide variety of treatment which has been studied until these days. The present study offers a literature review on the treatment of oral candidiasis, with the purpose of establish which treatment is the most suitable in each case. Searching the 24 latest articles about treatment of candidiasis it concluded that the incidence depends on the type of the candidiasis and the virulence of the infection. Although nystatin and amphotericin b were the most drugs used locally, fluconazole oral suspension is proving to be a very effective drug in the treatment of ora…

Drugmedicine.medical_specialtyOral Medicine and Pathologybusiness.industryItraconazolemedia_common.quotation_subjectAntifungal drugsIncidence (epidemiology)ResearchOdontologíaPharmacology:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludNystatinAmphotericin BUNESCO::CIENCIAS MÉDICASmedicineKetoconazolebusinessGeneral DentistryFluconazolemedia_commonmedicine.drug
researchProduct